Evidence map›Paper›PMID 37415228›Full record

ArticleBMC research notes2023

Topology and adenocarcinoma cell localization dataset on the labyrinthin diapeutic biomarker.

Ankit Sharma, Michael Babich, Tianhong Li, James A Radosevich

Open access · goldAbstract read
In one paragraph

Article in BMC research notes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ankit SharmaLabyRx Immunologic Therapeutics Limited, 2700 Stockton Blvd, Sacramento, CA, 95817, USA.
Michael BabichLabyRx Immunologic Therapeutics Limited, 2700 Stockton Blvd, Sacramento, CA, 95817, USA.
Tianhong LiDivision of Hematology & Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
James A RadosevichLabyRx Immunologic Therapeutics Limited, 2700 Stockton Blvd, Sacramento, CA, 95817, USA. jrados@labyrx.com.
University of California, Davis · US

Funding

Humanized antibodies against a new adencoarcinoma targetR43CA108222 · NCI · IMMVARX, INC. · PI BABICH, MICHAEL · 2004 to 2004
$100k
NCI NIH HHS R43 CA108222
6 · The paper itself

Abstract

objectiveThe discovery and characterization of tumor associated antigens is increasingly important to advance the field of immuno-oncology. In this regard, labyrinthin has been implicated as a neoantigen found on the cell surface of adenocarcinomas. Data on the (1) topology, (2) amino acid (a.a.) homology analyses and (3) cell surface localization of labyrinthin by fluorescent activated cell sorter (FACS) are studied in support of labyrinthin as a novel, pan-adenocarcinoma marker.

resultsBioinformatics analyses predict labyrinthin as a type II protein with calcium binding domain(s), N-myristoylation sites, and kinase II phosphorylation sites. Sequence homologies for labyrinthin (255 a.a.) were found vs. the intracellular aspartyl/asparaginyl beta-hydroxylase (ASPH; 758 a.a.) and the ASPH-gene related protein junctate (299 a.a.), which are both type II proteins. Labyrinthin was detected by FACS on only non-permeablized A549 human lung adenocarcinoma cells, but not on normal WI-38 human lung fibroblasts nor primary cultures of normal human glandular-related cells. Microscopic images of immunofluorescent labelled MCA 44-3A6 binding to A549 cells at random cell cycle stages complement the FACS results by further showing that labyrinthin persisted on the cell surfaces along with some cell internalization for greater than 20 min.

Indexed as

AdenocarcinomaLung NeoplasmsBiomarkersCalcium-Binding ProteinsHumansBiomarkersCalcium-Binding ProteinsAdenocarcinomaASPHBiomarkerLabyrinthinNeo-antigenPan-tumor targetTumor associated antigenTumor specific antigen

Identifiers

PMID37415228
PMCPMC10326932
OpenAlexW4383341565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.